DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: Image cytometric DNA analysis in formalin-fixed tissues

American Journal of Gastroenterology

Volumn 99, Issue 10, 2004, Pages 1887-1894

  Fang, Ming ^b   Lew, Edward ^b   Klein, Michael ^b   Sebo, Thomas ^b   Su, Yingyao ^b   Goyal, Raj ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIPLOIDY; DNA CONTENT; DNA DAMAGE; DNA DETERMINATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HIGH GRADE DYSPLASIA; HUMAN; HUMAN TISSUE; IMAGE CYTOMETRY; INTESTINE METAPLASIA; LOW GRADE DYSPLASIA; MALE; MARKER GENE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPECIALIZED INTESTINAL METAPLASIA; TISSUE SECTION;

ADENOCARCINOMA; AGED; BARRETT ESOPHAGUS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FIXATIVES; FORMALDEHYDE; HUMANS; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; RISK FACTORS;

EID: 7044286361     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.30886.x     Document Type: Article

References (40)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83(10):2049-53.
2. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(5 suppl 15):2-8.
3. Paull A, Trier JS, Dalton MD, et al. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295(9):476-80.
4. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986;315(6):362-71.
5. Cameron AJ. The epidemiology and prevalence of Barrett's esophagus and adenocarcinoma. In: Sharma P, Sampliner RE, eds. Barrett's esophagus and adenocarcinoma. Maiden, MA: Blackwell Science Inc., 2001:8-17.
6. Spechler SJ. Screening and surveillance for complications related to gastroesophageal reflux disease. Am J Med 2001;111(suppl 8A):130S-136S.
7. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119(2):333-8.
8. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002;287(15):1972-81.
9. Geboes K, Van Eyken P. The diagnosis of dysplasia and malignancy in Barrett's oesophagus. Histopathology 2000;37(2):99-107.
10. Falk GW. Screening and surveillance of Barrett's esophagus. In: Sharma P, Sampliner RE, eds. Barrett's esophagus and adenocarcinoma. Maiden, MA: Blackwell Science Inc., 2001:89-105.
11. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120(7):1607-19.
12. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95(7):1669-76.
13. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19(2):166-78.
14. Baak JP, ten Kate FJ, Offerhaus GJ, et al. Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies. J Clin Pathol 2002;55(12):910-6.
15. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002;51(5):671-6.
16. van Sandick JW, Baak JP, van Lanschot JJ, et al. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol 2000;190(2):177-83.
17. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: Thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34(6):257-63.
18. Susnik B, Poulin N, Phillips D, et al. Comparison of DNA measurement performed by flow and image cytometry of embedded breast tissue sections. Anal Quant Cytol Histol 1995;17(3):163-71.
19. Danesi DT, Spano M, Altavista P. Quality control study of the Italian group of cytometry on flow cytometry cellular DNA content measurements. Cytometry 1993;14(5):576-83.
20. Alanen KA, Lintu M, Joensuu H. Image cytometry of breast carcinomas that are DNA diploid by flow cytometry: Time to revise the concept of DNA diploidy. Anal Quant Cytol Histol 1998;20(3):178-86.
21. Bacus JW, Bacus JV. Quality control in image cytometry: DNA ploidy. J Cell Biochem Suppl 1994;19:153-64.
22. Sebo TJ. Digital image analysis. Mayo Clin Proc 1995;70(1):81-2.
23. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25(10):982-93.
24. Reid BJ, Haggitt RC, Rubin CE, et al. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93(1):1-11.
25. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102(4pt 1):1212-9.
26. Menke-Pluymers MB, Hop WC, Mulder AH, et al. DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Hepatogastroenterology 1995;42(6):786-8.
27. Menke-Pluymers MB, van Drunen E, Vissers KJ, et al. Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. Cancer Genet Cytogenet 1996;90(2):109-17.
28. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 1989;96(5 pt 1):1249-56.
29. Atkinson M, Iftikhar SY, James PD, et al. The early diagnosis of oesophageal adenocarcinoma by endoscopic screening. Eur J Cancer Prev 1992;1(4):327-30.
30. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92(2):212-15.
31. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93(4):536-41.
32. van Sandick JW, van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43(2):216-22.
33. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94(8):2037-42.
34. Reid BJ, Sanchez CA, Blount PL, et al. Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105(1):119-29.
35. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32(4):379-88.
36. James PD, Atkinson M. Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus. Gut 1989;30(7):899-905.
37. Khan M, Bui HX, del Rosario A, et al. Role of DNA content determination by image analysis in confirmation of dysplasia in Barrett's esophagus. Mod Pathol 1994;7(2):169-74.
38. Fennerty MB, Sampliner RE, Way D, et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97(4):815-20.
39. Weston AP, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95(8):1888-93.
40. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: A systematic review. Gastroenterology 2002;122(1):26-33.